Home » Hemoglobinopathies Market Size, Share and Report 2022-2027

Hemoglobinopathies Market Size, Share and Report 2022-2027

by Alex Hales

Hemoglobinopathies Market Overview:

According to the latest report by IMARC Group, titled “Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” offers a comprehensive analysis of the industry, which comprises insights on the global hemoglobinopathies market. The report also includes competitor and regional analysis, and contemporary advancements in the market.

The global hemoglobinopathies market reached a value of US$ 8.36 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 14.8 Billion by 2027 exhibiting a CAGR of 9.50% during 2022-2027.

Hemoglobinopathies represent a group of genetic blood disorders that cause structural and production abnormalities in hemoglobin molecules. They are detected by genetic testing, high-performance liquid chromatography, routine red blood cell count, hemoglobin isoelectric focusing, hemoglobin electrophoresis test, etc. Some of the common variants of hemoglobinopathies include sickle cell, thalassemia, beta-thalassemia, etc. Antibiotics, ACE inhibitors, blood transfusions, hydroxyurea, stem-cell transplantation, and analgesic are widely utilized as hemoglobinopathies treatment solutions.

Request a PDF Sample Copy for more detailed market insights: https://www.imarcgroup.com/hemoglobinopathies-market/requestsample

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Hemoglobinopathies Market Trends and Drivers:

The rising prevalence of numerous medical conditions, including sickle cell disease (SCD) and thalassemia, is one of the key factors driving the hemoglobinopathies market. In line with this, the expanding geriatric population, who are more susceptible to several chronic ailments, including anemia, is further catalyzing the market growth.

Moreover, the inflating adoption of gene therapy for the treatment of hemoglobinopathies at affordable costs is acting as another significant growth-inducing factor. In line with this, the launch of various favorable policies by government bodies across countries to introduce novel therapies and the growing healthcare sector are also augmenting the global market.

Additionally, the increasing investments in R&D activities to develop CRISPR-Cas9 technology by adding, editing, removing, altering, and modifying the DNA are anticipated to fuel the hemoglobinopathies market over the forecasted period.

Explore Full Report with TOC & List of Figures: https://www.imarcgroup.com/hemoglobinopathies-market

Important Note: If the link is not clickable please open it in a new tab, you will get detailed analysis of the market, growth analysis graphs, historical period analysis, forecast period analysis, major market segmentation, top leading key players of the market, table of content, list of figures, and list of tables.

Global Hemoglobinopathies Market 2022-2027 Analysis and Segmentation:

 Competitive Landscape:

 The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

  • Bio-Rad Laboratories Inc.
  • bluebird bio Inc.
  • Bristol-Myers Squibb Company
  • Danaher Corporation
  • Emmaus Life Sciences Inc.
  • Gamida-Cell Ltd.
  • Global Blood Therapeutics Inc.
  • Novartis AG
  • PerkinElmer Inc.
  • Pfizer Inc.
  • Prolong Pharmaceuticals LLC
  • Sangamo Therapeutics Inc.
  • Sysmex Corporation

The report has segmented the market on the basis of region, type, treatment, test type and end user.

Breakup by Type:

  • Thalassemia
    • Alpha Thalassemia
    • Beta Thalassemia
  • Sickle Cell Disease
  • Others

Breakup by Treatment:

  • Blood Transfusion
  • Stem-cell Transplantation
  • Analgesics
  • Antibiotics
  • ACE Inhibitors
  • Hydroxyurea
  • Others

Market Breakup by Test Type:

  • Red Blood Cell (RBC) Count
  • Genetic Testing
  • High Performance Liquid Chromatography (HPLC)
  • Hemoglobin Isoelectric Focusing (Hb IEF)
  • Hemoglobin Electrophoresis (Hb ELP)
  • Hemoglobin Solubility Test

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostics Laboratories
  • Others

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

 If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

 Key highlights of the report:

  • Market Performance (2016-2021)
  • Market Outlook (2022- 2027)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Read More

Related Posts

Leave a Comment